Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy

NCT07633236 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Oncology Patients Receiving Chemotherapy
Cachexia-Anorexia Syndrome
Oncology

Interventions

DRUG: OLANZapine 2.5 MG

Sponsor

Blokhin's Russian Cancer Research Center